GB0903913D0 - Compositions and methods - Google Patents

Compositions and methods

Info

Publication number
GB0903913D0
GB0903913D0 GBGB0903913.2A GB0903913A GB0903913D0 GB 0903913 D0 GB0903913 D0 GB 0903913D0 GB 0903913 A GB0903913 A GB 0903913A GB 0903913 D0 GB0903913 D0 GB 0903913D0
Authority
GB
United Kingdom
Prior art keywords
compositions
methods
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
GBGB0903913.2A
Other languages
English (en)
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Medical Research Council
Original Assignee
Medical Research Council
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Medical Research Council filed Critical Medical Research Council
Priority to GBGB0903913.2A priority Critical patent/GB0903913D0/en
Publication of GB0903913D0 publication Critical patent/GB0903913D0/en
Priority to CA2750911A priority patent/CA2750911A1/en
Priority to DK10710598.3T priority patent/DK2403515T3/da
Priority to JP2011552505A priority patent/JP5670921B2/ja
Priority to CN201080009932.2A priority patent/CN102341117B/zh
Priority to ES10710598.3T priority patent/ES2493619T3/es
Priority to PCT/GB2010/000391 priority patent/WO2010100428A2/en
Priority to EP10710598.3A priority patent/EP2403515B1/en
Priority to US13/254,081 priority patent/US9089565B2/en
Priority to HK12106832.5A priority patent/HK1166017B/en
Priority to AU2010219463A priority patent/AU2010219463A1/en
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/45—Transferases (2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10—Transferases (2.)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10—Transferases (2.)
    • C12N9/12—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
    • C12N9/1205—Phosphotransferases with an alcohol group as acceptor (2.7.1), e.g. protein kinases
    • C12N9/1211—Thymidine kinase (2.7.1.21)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Enzymes And Modification Thereof (AREA)
GBGB0903913.2A 2009-03-06 2009-03-06 Compositions and methods Ceased GB0903913D0 (en)

Priority Applications (11)

Application Number Priority Date Filing Date Title
GBGB0903913.2A GB0903913D0 (en) 2009-03-06 2009-03-06 Compositions and methods
AU2010219463A AU2010219463A1 (en) 2009-03-06 2010-03-05 Protein kinase A and/or casein kinase II for alleviating the inhibition of neurite outgrowth
CN201080009932.2A CN102341117B (zh) 2009-03-06 2010-03-05 用于缓解神经突生长抑制的蛋白激酶a和/或酪蛋白激酶ii
DK10710598.3T DK2403515T3 (da) 2009-03-06 2010-03-05 Sammensætninger og fremgangsmåder til at forårsage neurit-udvækst
JP2011552505A JP5670921B2 (ja) 2009-03-06 2010-03-05 神経突起伸長阻害の軽減のためのプロテインキナーゼａ及び／又はカゼインキナーゼｉｉ
CA2750911A CA2750911A1 (en) 2009-03-06 2010-03-05 Compositions and methods
ES10710598.3T ES2493619T3 (es) 2009-03-06 2010-03-05 Composiciones y métodos para provocar el crecimiento de neuritas
PCT/GB2010/000391 WO2010100428A2 (en) 2009-03-06 2010-03-05 Compositions and methods
EP10710598.3A EP2403515B1 (en) 2009-03-06 2010-03-05 Compositions and methods for causing neurite outgrowth.
US13/254,081 US9089565B2 (en) 2009-03-06 2010-03-05 Compositions and methods for causing neurite outgrowth
HK12106832.5A HK1166017B (en) 2009-03-06 2010-03-05 Compositions and methods for causing neurite outgrowth

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB0903913.2A GB0903913D0 (en) 2009-03-06 2009-03-06 Compositions and methods

Publications (1)

Publication Number Publication Date
GB0903913D0 true GB0903913D0 (en) 2009-04-22

Family

ID=40600640

Family Applications (1)

Application Number Title Priority Date Filing Date
GBGB0903913.2A Ceased GB0903913D0 (en) 2009-03-06 2009-03-06 Compositions and methods

Country Status (10)

Country Link
US (1) US9089565B2 (enExample)
EP (1) EP2403515B1 (enExample)
JP (1) JP5670921B2 (enExample)
CN (1) CN102341117B (enExample)
AU (1) AU2010219463A1 (enExample)
CA (1) CA2750911A1 (enExample)
DK (1) DK2403515T3 (enExample)
ES (1) ES2493619T3 (enExample)
GB (1) GB0903913D0 (enExample)
WO (1) WO2010100428A2 (enExample)

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU3214099A (en) 1998-04-03 1999-10-25 Curagen Corporation Lyst protein complexes and lyst interacting proteins
US6903187B1 (en) * 2000-07-21 2005-06-07 Allergan, Inc. Leucine-based motif and clostridial neurotoxins
JP2005508631A (ja) * 2001-07-17 2005-04-07 インサイト・ゲノミックス・インコーポレイテッド 受容体および膜結合タンパク質
JP2003093056A (ja) 2001-09-26 2003-04-02 Japan Science & Technology Corp ｐ５３のＳｅｒ４６をリン酸化する酵素
JP2007526440A (ja) 2003-06-03 2007-09-13 バイエル・ヘルスケア・エルエルシー 携帯型医療診断装置
GB0314943D0 (en) * 2003-06-25 2003-07-30 Proteome Sciences Plc Screening methods
CN1849132A (zh) * 2003-09-10 2006-10-18 伦敦大学国王学院 调节神经元生长的化合物以及它们的用途
CA2549000A1 (en) * 2003-12-16 2005-06-30 Children's Medical Center Corporation Method for treating neurological disorders
US20050214288A1 (en) * 2004-03-26 2005-09-29 Human Genome Sciences, Inc. Antibodies against Nogo receptor
EP1789070B1 (en) 2004-08-03 2012-10-24 Biogen Idec MA Inc. Taj in neuronal function
US7414637B2 (en) * 2004-09-10 2008-08-19 Telmap Ltd. Placement of map labels
CA2684321A1 (en) 2007-03-21 2008-09-25 Effat Emamian Compositions comprising pkac fragments and uses thereof for inhibiting akt1, p70s6k or abl activity

Also Published As

Publication number Publication date
JP2012519676A (ja) 2012-08-30
EP2403515A2 (en) 2012-01-11
DK2403515T3 (da) 2014-08-11
CN102341117A (zh) 2012-02-01
ES2493619T3 (es) 2014-09-12
WO2010100428A3 (en) 2010-10-21
HK1166017A1 (en) 2012-10-19
US20110318326A1 (en) 2011-12-29
EP2403515B1 (en) 2014-05-21
WO2010100428A2 (en) 2010-09-10
US9089565B2 (en) 2015-07-28
CN102341117B (zh) 2015-01-21
AU2010219463A1 (en) 2011-09-22
JP5670921B2 (ja) 2015-02-18
CA2750911A1 (en) 2010-09-10

Similar Documents

Publication Publication Date Title
SI3812360T1 (sl) Monoklorotrifluoropropenske spojine in sestavki ter postopki, ki jih uporabljajo
IL210153A0 (en) Nutrigenomics methods and compositions
ZA201103416B (en) Anti-cxcr1 compositions and methods
IL219891A0 (en) Lipopeptide compositions and related methods
PH12013500698A1 (en) Hair-mending compositions and associated methods
GB0819530D0 (en) Methods and compositions
IL210559A0 (en) Novel compositions and methods
GB0903299D0 (en) Composition and methods
GB0912468D0 (en) Composition and method
SG10201505149WA (en) Novel compositions and methods
GB0817585D0 (en) Novel compositions and methods
EP2512483A4 (en) BALAGLITAZON COMPOSITIONS AND METHOD THEREFOR
EP2490536A4 (en) COMPOSITION AND METHOD
GB201018650D0 (en) Methods and compositions
GB0902429D0 (en) Compositions and their use
GB0901494D0 (en) Compositions and Methods
ZA201200260B (en) Polyphenylsulphone-polytetrafluroethylene compositions and use thereof
GB0811250D0 (en) Methods and compositions
GB0901667D0 (en) Composition and method
EP2488624A4 (en) STABILIZED SURFACTANT-OXIDANT COMPOSITIONS AND METHODS THEREOF
GB0909792D0 (en) Composition and uses thereof
GB0908498D0 (en) Compositions and methods
GB0909720D0 (en) Compositions and methods
GB0907616D0 (en) Methods and compositions
GB0901899D0 (en) Compositions and uses

Legal Events

Date Code Title Description
AT Applications terminated before publication under section 16(1)